Home/Pipeline/GIGA-2339

GIGA-2339

Chronic Hepatitis B Virus (HBV)

Phase 1Active

Key Facts

Indication

Chronic Hepatitis B Virus (HBV)

Phase

Phase 1

Status

Active

Company

GigaGen

About GigaGen

GigaGen is pioneering a novel class of recombinant polyclonal antibody drugs using its industry-leading single-cell technology platforms. Its pipeline includes a Phase 1 anti-CTLA-4 monoclonal antibody (GIGA-564) for oncology and a Phase 1 recombinant polyclonal (GIGA-2339) for Hepatitis B, alongside significant biodefense contracts. As a Grifols subsidiary, the company combines innovative discovery capabilities with the resources and manufacturing expertise of a global plasma leader, positioning it to advance potent, engineered antibody therapies for complex diseases.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases Immunodeficiencies Biodefense

Other Chronic Hepatitis B Virus (HBV) Drugs

Drug	Company	Phase	Status
CRMA-1001	nChroma Bio	Phase 1/2	Active